Unlock stock picks and a broker-level newsfeed that powers Wall Street.
1.2500
0.0000
(0.00%)
At close: April 2 at 4:00:00 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Mark Manfredi Ph.D. | President, CEO & Director | 868.19k | -- | 1972 |
| Dr. Jotin Marango M.D., Ph.D. | COO, CFO, Head of Corporate Development & Treasurer | 809.95k | -- | 1980 |
| Ms. Rebecca Cohen | Vice President of Investor Relations, Corporate Strategy & Communication | -- | -- | -- |
| Mr. Jeffrey Ecsedy Ph.D. | Chief Development Officer | -- | -- | 1970 |
| Mr. Bob Lally | Senior Vice President of Finance & Operations | -- | -- | -- |
| Mr. David Damphousse M.S. | Senior Vice President of Clinical Development Operations | -- | -- | -- |
| Mr. Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations | -- | -- | -- |
Ikena Oncology, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 10
Description
Ikena Oncology, Inc. operates as an oncology company in the United States. The company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. The company develops IK-595, a molecular glue which is in Phase 1 clinical trial to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts
Corporate Governance
Ikena Oncology, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 10; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 12, 2025 at 10:59 AM UTC - May 16, 2025 at 12:00 PM UTC
Ikena Oncology, Inc. Earnings Date
Recent Events
January 10, 2025 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Related Tickers
PMVP PMV Pharmaceuticals, Inc.
1.0000
-0.99%
TRAW Traws Pharma, Inc.
2.3200
+8.41%
ANTX AN2 Therapeutics, Inc.
1.4000
+1.45%
FNCH Finch Therapeutics Group, Inc.
14.25
+7.47%
THRD Third Harmonic Bio, Inc.
3.5500
+5.65%
EPIX ESSA Pharma Inc.
1.5800
+1.28%
OKUR OnKure Therapeutics, Inc.
4.1300
-3.05%
HLVX HilleVax, Inc.
1.5000
+8.30%
BOLT Bolt Biotherapeutics, Inc.
0.4010
+2.27%
KZR Kezar Life Sciences, Inc.
4.6000
+2.00%